They mentioned how the BioTech was up today.And in the upper right corner of my screen was a large box with 4 BioTechs they mentioned were up.Exelixis was on the top of the list.That's all there was.But that was nice to see.
Clem there is little importance to this Patent Abstract.The main person doing the research is a Sanofi Dr. and Aftab had some involvement. This is not anything france needed to alert us to. It has little effect on Exel. It's all preclinical work concenring the inhibitors of PI3K. It would being many years till anything of consequence results from it. France didn't have the decency to answer you Clem and enabler had no call for his snide remark. Take it easy Chem and good luck.
All that matters is having drugs approved with a big market for them. Will Metero be a winner? Or another disaster like the Prostate results. We heard from all kinds of people that presented what was thought to be very promising trial info. and that some of the most well known Dr.s in the field seemed to feel really confident about Cabo for prostate treatment and it failed. All the indications that Cabo resolved bone problems and seemed to make bones recover or ,say, improve. In the end all that proved to be was a pipe dream. Until the FDA approves Cobi for some disease with a larger market than MTC or Roche gets approval for the Melanonma drug and for a large number of those people recieve it Exel is going no where. All the up and down price movement is maybe by speculation or unscrupulous manipulation no one here knows; we can all guess. Be my guest to continue all the chatter.
Just like everyone. He can only prophesy. He maybe right, he maybe wrong. He sure used lots of intelligent thoughts. But even the Great Ernie was proven wrong sometimes.
It was reported; it was due to the good qtly. report. I also would think the big boys, that are important, know Genentech has begun a search for high level scientists, Doctors, for studies of Cobi. Genentech certainly has a lot of faith in Cobi to push ahead like they are!
Did one of them present some results which are better for the same indications than Exel has reported? That would be the reason for the share price drop. My joy with the early price increase certainly were dash in the late afternoon and today!
CRs are what?
Would it be in Webster's dictionary?
Stifel reported it is too toxic. It's on the TD Amertrade page.
I have had a lot of shares for well over 10 yrs; in the Exel 401K plan. I sure want the price to return to what it was yrs. ago well over $12. I was feeling good when the price was going up a little and vol. was high, the last few days. But now toxicity is appearing again. This is not the first time this has come up. This was part of it's down fall before. Again I'm not happy about that today.
Nothing like misquoting. He said 60mg not 160mg as you stated. " data in this indication and others to be presented at ASCO, will support our contention that 60 mg is too intolerable for patients, which could bode poorly for the ongoing Phase 3 METEOR trial which employs this dose in relatively healthy RCC patients."Toxic side affects have long been a problem for Cabo; unfortunately.